Merck & Co mauled as forecasts fall short
Shares in Merck & Co (NYSE: MRK) were more than 10% lower during Tuesday’s early trading in New York after the US pharma giant announced its second-quarter financial results and latest guidance for 2024.
Worldwide sales hit $16.11 billion, up 7% year-over-year and ahead of analysts’ expectations. Merck's adjusted earnings reversed from a year-earlier loss to $2.28 per share, beating Wall Street's forecast for $2.16.
For the year, the company narrowed its sales outlook and now expects $63.4 billion to $64.4 billion. Merck also cut its adjusted earnings outlook $0.60 at the midpoint, to $7.94 to $8.04 per share. Analysts were expecting earnings of $8.16 a share and sales of $64.29 billion, with Merck’s more pessimistic view perhaps explaining the stock market reaction.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze